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Abstract
Background: Graft-versus-host disease (GVHD) after liver transplantation (LT) is a rare but
serious complication. The aim of this study is to identify risk factors, including
immunosuppressive regimens, for mortality due to GVHD (fatal GVHD).
Methods: Using data from the OPTN/UNOS registry, 77,416 adult patients who underwent

TE
D

LT between 2003 and 2018 were assessed. Risk factors for fatal GVHD were analyzed by
focusing on induction and maintenance immunosuppression regimens.

Results: The incidence of fatal GVHD was 0.2% (121/77,416), of whom 105 (87%) died

within 180 days and 13 (11%) died between 181 days and 1 year. Median survival after LT
was 68.0 (49.5-125.5) days. Recipient age minus donor age greater than 20 years (HR 2.57,

EP

P<0.001) and basiliximab induction (HR 1.69, P=0.018) were independent risk factors for

fatal GVHD. Maintenance therapy with mycophenolate mofetil (MMF) was associated with a
decrease in fatal GVHD (HR 0.51, P=0.001). In an increased risk cohort of patients with

C
C

recipient-donor age discrepancy greater than 20 years, MMF use was associated with a 50%
decline in fatal GVHD (HR 0.50, P<0.001).
Conclusions: Recipient age minus donor age greater than 20 years remains a significant risk

A

factor for fatal GVHD. The risk of fatal GVHD significantly increases in association with
basiliximab induction and decreases with MMF maintenance. These associations were
pronounced in patients with recipient minus donor age greater than 20 years. These results
emphasize the importance of donor age and individualized immunosuppression regimens on
the risk of fatal GVHD.
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Introduction
Graft-versus-host disease (GVHD) is a rare but often fatal complication after liver
transplantation (LT). The incidence is estimated to be 0.2-2%,1,2 but the mortality rate can be
up to 85%.2 GVHD occurs when donor immunocompetent T lymphocytes recognize host
cells as foreign and mount an immune response against recipient organs.3,4
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Several potential risk factors for developing GVHD after LT have been identified. A
graft with closely matching HLA to the recipient is a well-described risk factor.2,5,6 Other
reported risk factors include recipient age over 65 years, an increased older recipient to

younger donor age discrepancy,7-9 blood transfusion before LT, immunosuppressive regimen
or immunodeficiency status before LT, heightened immunosuppression early posttransplant,

EP

and rejection.2,5,6,10-12 However, the effects of immunosuppression regimens on the
occurrence of GVHD, in association with accepted risk factors, remain unclear.

We hypothesized that induction and maintenance immunosuppression regimens might

C
C

affect the incidence of mortality due to GVHD (fatal GVHD) in LT patients. The aim of this

study is to identify risk factors for fatal GVHD after LT, with a focus on differences in
immunosuppression which are modifiable.

A

Materials and Methods
Patient cohort

This study used data from the Organ Procurement and Transplantation Network and United

Network for Organ Sharing (OPTN/UNOS) contained in the Standard Transplant Analysis
and Research file, which includes data on all patients who received LT in the United States.
Adult transplant patients (≥ 18 years old) between January 1, 2003 and March 31, 2018 were
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evaluated. Patients who underwent LT combined with thoracic organs, intestine and/or
pancreas and those who died within 30 days of LT were excluded. This study was approved
for an institutional review board (IRB) waiver after IRB review.
Study design
Patients with posttransplant mortality due to GVHD were identified by a recipient primary

TE
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cause of death code, “COD”, of “GRAFT VS. HOST DISEASE (4615)” in the STAR file.
Patients with mortality due to GVHD were compared to all other patients to determine

possible risk factors for fatal GVHD. Recipient and donor characteristics were evaluated as
well as immunosuppression regimens, including induction and maintenance agents. Among
induction agents, we evaluated basiliximab, rabbit anti-thymocyte globulin (rATG), steroids,

EP

and rituximab. Patients who received other induction agents, including alemtuzumab,

daclizumab, muromonab, and anti-lymphocyte globulin, were excluded due to the small
sample size. Subgroup analysis was conducted according to recipient-donor age discrepancy

C
C

and risk factors for fatal GVHD were analyzed in each group. The cut-off for recipient minus
donor age discrepancy was defined based on receiver operating characteristic (ROC) curve
analysis (Figure S1 http://links.lww.com/TP/C98 ). Since the optimal cut-off value was found

A

to be 20 years in the ROC curve, patients were categorized into 2 groups: recipient minus
donor age ≤ 20 years and > 20 years.

Statistical analysis
Data were summarized using the median with interquartile range for continuous variables and
using percentage for discrete variables. Comparisons of continuous variables and discrete
variables were performed using the Mann-Whitney U test and chi-square test. ROC curve
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analysis for overall GVHD mortality was used to determine the optimal cutoff value for
recipient minus donor age discrepancy. Risk factors and hazard ratios for posttransplant
mortality were analyzed using Cox proportional hazards models. Variables with a P-value
less than 0.05 in univariable analysis were included in the multivariable model. In the
subgroup analysis, variables that were significant in univariable analysis were included in the

TE
D

multivariable model. A Gray test was used to estimate the cumulative incidence of competing
events including fatal GVHD and overall mortality. P <0.05 was considered statistically

signiﬁcant. All statistical analyses were completed by using SPSS version 25 (IBM, Chicago,
USA) and EZR version 1.37 (Saitama, Japan) which is a graphical user interface for R (The R

Results

EP

Foundation for Statistical Computing, Vienna, Austria).

Patient characteristics

A total of 83 822 adult patients underwent LT during the study period. Of these, 206 patients

C
C

who received LT combined with thoracic organs, intestine, and/or pancreas, and 6212 patients

who died within 30 days of LT were excluded. A total of 77 416 patients were evaluated.
Median follow-up period was 3.9 (1.3-7.1) years. With regard to recipient characteristics, the

A

median age (IQR) was 56.0 (49.0-62.0) years, and the median laboratory Model for End-

Stage Liver Disease (MELD) score was 21 (14-30). rATG and basiliximab were used for
induction in 7488 (9.7%) and 11 736 patients (15.2%), respectively. Mycophenolate mofetil
(MMF) was used as maintenance therapy at the time of first discharge after LT in 53 309
patients (68.9%). The median donor age was 41.0 (26.0-54.0) years old. Median age
discrepancy was 13.0 (0-28.0) years. A complete HLA match and class I match were recorded
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in 97 patients (0.1%) and 192 patients (0.2%), respectively. However, complete and class I
HLA match data were missing in 57.7 and 57.5% of LT patients.
In 121 patients with fatal GVHD, a secondary cause of death was reported in 47 patients.
Among them, 34 patients had infection, 2 had malignancy, and 1 had a biliary complication.
Posttransplant mortality due to GVHD and comparison of background characteristics

TE
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Of the 77 416 LT patients, 121 (0.2%) died from GVHD during the study period. The median
survival after LT for these patients was 68.0 (49.5-125.5) days. One hundred five patients

died within 180 days, 13 patients died between 181 days and 1 year, 2 patients died between
1 and 2 years and 1 patient died more than 2 years after LT.

We compared background characteristics between patients who died from GVHD

EP

(n=121) and all others (n=77 295). There were no differences in underlying liver disease

(Table 1). The fatal GVHD group showed significantly older recipient age (60.0 years vs.
56.0 years; P<0.001) and higher rates of diabetes (30.6% vs. 22.3%; P=0.034). Patients in the

C
C

fatal GVHD group received induction therapy with basiliximab more frequently (22.3% vs.
15.1%; P=0.037) and maintenance therapy with MMF less frequently (56.2% vs. 68.9%;

P=0.004). The distribution of patients according to transplant year was similar between the

A

two groups. In terms of donor characteristics, patients in the fatal GVHD group received
younger donors (31.0 years vs. 41.0 years; P<0.001) and had a greater recipient minus donor
age discrepancy (25.0 years vs. 13.0 years; P<0.001). The proportion of donation after

circulatory death donors was comparable between 2 groups. Of the 121 patients with fatal
GVHD, 74 (61.1%) had recipient minus donor age discrepancy > 20 years vs. 28 885 of
77 293 (37.3%) for all others. The incidence of HLA complete match (5.9% vs. 0.3%;
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P<0.001) and HLA class I match (10.3% vs. 0.6%; P<0.001) was higher in the fatal GVHD
group than in all others, whereas the incidence of gender mismatch was comparable between
2 groups (Table 1).
Risk factors for fatal GVHD
On univariable analysis, recipient minus donor age discrepancy > 20 years (hazard ratio [HR]
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2.64, 95% confidence interval [CI] 1.83-3.80; P<0.001), recipient diabetes (HR 1.55, 95% CI
1.05-2.28; P=0.027), induction therapy with basiliximab (HR 1.62, 95% CI 1.05-2.48;

P=0.028), HLA complete match (HR 21.82, 95% CI 7.95-59.91; P<0.001), and HLA class I
match (HR 19.92, 95% CI 9.11-43.54; P<0.001) were associated with fatal GVHD.

Maintenance therapy with MMF was associated with a significant decrease in the risk of fatal

EP

GVHD (HR 0.57, 95% CI 0.40-0.82; P=0.002).

Multivariable analysis showed recipient minus donor age discrepancy > 20 years (HR
2.57, 95% CI 1.78-3.71; P<0.001) and induction therapy with basiliximab (HR 1.69, 95% CI

C
C

1.10-2.61; P=0.018) were independent risk factors for fatal GVHD. Maintenance therapy

with MMF was associated with a significant 49% decline in mortality (HR 0.51, 95% CI
0.35-0.75; P=0.001). In this multivariable analysis, HLA match data were not included

A

because of the large number of missing values (Table 2).
The result of multivariable analysis, including HLA complete match data, is shown in

Table S1 http://links.lww.com/TP/C98 . HLA complete match was an independent risk factor

for fatal GVHD (HR 25.89, 95% CI 9.36-71.59; P<0.001). In this model, recipient minus
donor age discrepancy > 20 years (HR 1.74, 95% CI 1.08-2.81; P=0.023) and basiliximab
induction (HR 1.78, 95% CI 1.05-3.04; P=0.034) remain as independent risk factors.
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Adjusted risks of fatal GVHD according to immunosuppression regimens
Adjusted hazards of fatal GVHD were compared between immunosuppression regimens.
Induction therapy with basiliximab was associated with an increase in fatal GVHD (HR 1.84,
95% CI 1.18-2.88; P=0.008) whereas induction therapy with rATG, corticosteroids or
rituximab was not a risk factor. The use of MMF was associated with a protective effect for
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fatal GVHD (HR 0.50, 95% CI 0.33-0.74; P<0.001, Figure 1).
Risk factors for fatal GVHD according to age discrepancy

Risk factors for posttransplant mortality due to GVHD were analyzed separately according to
recipient minus donor age discrepancy. In the larger age discrepancy group (>20 years),

multivariable analysis revealed that diabetes at LT (HR 1.99, 95% CI 1.24-3.18; P=0.004)

EP

was significantly associated with fatal GVHD and maintenance therapy with MMF (HR 0.41,
95% CI 0.25-0.67; P<0.001) was associated with favorable outcomes. In the smaller age
discrepancy group (≤ 20 years), induction or maintenance immunosuppressive agents were

C
C

not associated with fatal GVHD. (Table 3).

Cumulative incidence of fatal GVHD according to immunosuppression regimens and
age discrepancy

A

The cumulative incidence of fatal GVHD within a year of LT was compared according to the
use of basiliximab (as induction) and MMF (as maintenance) in each age discrepancy group
(Figure 2). In patients who did not receive basiliximab, the MMF cohort had a significantly

lower cumulative incidence rate of fatal GVHD than those without MMF (P=0.018). In the
cohort of patients who received MMF, those who also received basiliximab had a
significantly higher incidence of fatal GVHD than those who did not receive basiliximab
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(P=0.038, Figure 2A). In evaluating the age discrepancy > 20 years group: in those that did
not receive basiliximab, patients who received MMF had a lower incidence of fatal GVHD
than those who did not receive MMF group (P=0.003). No impact of MMF or basiliximab
was observed in the age discrepancy ≤ 20 years group (Figure 2B and C).
Effect of transplant year on fatal GVHD

TE
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We compared recipient and donor age and the use of immunosuppression regimens across 3
era groups (2003-2007, 2008-2012, and 2013-2018). Recipient age was significantly older in
the years of 2013-2018 (P<0.001). Differences in donor age were not significant across eras.
Basiliximab induction and maintenance with MMF were more frequently used in 2013-2018
(P<0.001, Table S2 http://links.lww.com/TP/C98 ). Transplant year was not associated with

Discussion

EP

fatal GVHD (Table 2).

In this study, recipient minus donor age discrepancy > 20 years and basiliximab induction

C
C

were independent risk factors for fatal GVHD. In contrast, the use of MMF as a maintenance

immunosuppressant was associated with a decreased risk of fatal GVHD. Notably, the effects
of immunosuppression regimens were prominent in the greater recipient minus donor age

A

discrepancy group. These results emphasize that individualized immunosuppression regimens
according to recipient-donor age discrepancy may have a role in mitigating the risk of fatal
GVHD. Because of the low incidence of GVHD, many studies are case series from a single
center.9 To our best knowledge, this is the largest cohort that has been analyzed for risk
factors for fatal GVHD.
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Basiliximab is a chimeric monoclonal antibody with a high affinity for the alpha
subunit of the interleukin-2 receptor (IL-2R) of activated T lymphocytes.13 This binding
inhibits the proliferation of activated T lymphocytes. The use of basiliximab, as induction
therapy, reduces the rate and severity of acute cellular rejection following kidney and liver
transplantation.14,15 In this study, basiliximab induction was found to be an independent risk

TE
D

factor for fatal GVHD. Although the difference was not statistically significant, this finding
was more prominent in the larger recipient-donor age discrepancy group. Basiliximab is an
IL-2R alpha antagonist and IL-2R alpha expression is tightly restricted to activated T cells.
One possible explanation for the effect of basiliximab is that it may preferentially deplete

activated recipient T lymphocytes but not necessarily donor T lymphocytes. rATG would be

EP

expected to have a more indiscriminate effect on recipient and donor T lymphocytes. The use
of rATG was not associated with fatal GVHD. In fact, a protective effect of rATG against
GVHD is recognized in hematopoietic stem-cell transplantation (SCT).16

C
C

MMF suppresses the proliferation of B and T lymphocytes. In this study, the use of

MMF as maintenance therapy was associated with the decreased risk of fatal GVHD, which
might be explained by the possible suppression of donor lymphocyte proliferation. Although

A

no study has shown that MMF preferentially suppresses the proliferation of lymphocytes

derived from the donor graft, the efficacy of MMF as a prophylactic agent for GVHD has
been reported in bone marrow transplantation.17 The use of maintenance MMF allows for a

reduced dose of calcineurin inhibitor (CNI) which has been reported to benefit renal
function.18 The use of a lower dose of CNI in conjunction with MMF would be another
possible explanation for the decreased risk of fatal GVHD in patients receiving MMF.
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However, detailed information on maintenance CNI dosing is not available in the
OPTN/UNOS registry. Further investigation would be warranted to clarify the effect of
immunosuppression regimens on the occurrence of GVHD.
Large recipient minus donor age discrepancy is a well-known risk factor for GVHD,
and is consistent with the results of this study.2,8,11,19 Younger donors are considered to have a

TE
D

larger number of lymphocytes in their liver, and older recipients might be less able to reject
donor lymphocytes.2 The novelty of our study includes the analysis of the effects of

immunosuppression regimens on the occurrence of fatal GVHD according to recipient-donor
age discrepancy. Importantly, the negative impact of basiliximab induction and positive effect
of maintenance MMF were seen in the larger age discrepancy group and not seen in the lower

EP

age discrepancy group. We do not advocate for avoiding lower age donors in older recipients
because mortality from remaining on the waiting list can easily exceed that of fatal GVHD.
While the choice of immunosuppressive regimen is influenced by many factors, these

C
C

findings suggest a role for tailoring immunosuppression in high-risk cases, including those
with large recipient-donor age discrepancy.
Complete matching of all HLA and class I HLA profiles was significantly associated

A

with fatal GVHD. In the separate analysis shown in Table S1 http://links.lww.com/TP/C98 ,
complete matching of HLA was an independent risk factor for fatal GVHD, along with
recipient minus donor age discrepancy and use of basiliximab as induction
immunosuppression. Our results concur with previous reports that note matched HLA profiles
are a significant risk factor for GVHD in LT recipients.8,10 In living donor LT, donordominant one-way HLA matching is also a significant risk factor for fatal GVHD.20 In cases
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of closely matched HLA types, donor lymphocytes may not be recognized as foreign and may
persist in significant numbers which can be demonstrated by short tandem repeat assays.
However, over half of the patients have missing HLA data in the UNOS registry, which
precludes rigorous analyses. HLA types may not be universally checked in LT candidates.
Because GVHD in LT recipients is often fatal, HLA donor typing and analysis may be

TE
D

valuable, especially in younger donors intended for older recipients. It should be noted
complete and class I HLA matches are rare.

In the large age discrepancy group, diabetes was an independent risk factor for fatal
GVHD, which is consistent with a prior report.10 The negative effect of diabetes was also
more prominent when older recipients receive livers from younger donors. Diabetes can

EP

impair immune cell function.21,22 The recipient’s immune system would be affected by a
variety of factors including age, co-morbidities, poor performance status and frailty,

sarcopenia, and nutritional status. A lower Karnofsky score (poor performance status) would

C
C

be associated with an impaired host-immune system. However, there was no association with

the occurrence of fatal GVHD, likely because reasons for lower Karnofsky scores are
multifactorial. It may be beneficial to assess the recipient’s immune system with

A

consideration of underlying co-morbidities.
Limitations of this study include its retrospective nature and the use of the

OPTN/UNOS registry. While the registry contains a large cohort, it lacks some data
completely and has limited granularity in other areas. Because the data does not capture

nonfatal causes of GVHD, we are unable to make any comments on risk factors associated
with survival or on the efficacy of therapy. There is a lack of detailed clinical data on the
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onset of GVHD, HLA types, immunosuppressive dosing regimens and rationales for their
selection. There is no data on clinical manifestations and treatment of GVHD. In addition, the
reported number of fatal GVHD cases is small and it is likely that some cases were not
captured. We did not exclude fatal GVHD cases who had a secondary cause of death since the
onset of “secondary” complications and causation between GVHD and those complications
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D

cannot be captured. Despite these limitations, this study includes one of the largest cohorts
evaluated for risk factors for fatal GVHD using national LT data in the United States. The
findings of this study should provide important insights into the selection of

immunosuppression in high-risk patients. For future directions, it would helpful to have more
detailed immunosuppression information and the incidence, diagnostic process, clinical

EP

manifestations and outcomes of fatal and nonfatal GVHD in the OPTN/UNOS registry to

address the questions which are unanswered in this study. Multicenter studies or prospective
randomized studies are difficult to conduct due to the limited number of patients with GVHD

C
C

in liver transplant. GVHD remains uncommon. However, as overall transplant outcomes
improve, GVHD maybe a more prominent cause of morbidity and mortality.
In conclusion, this study demonstrates that the risk of fatal GVHD significantly

A

increases in association with basiliximab induction and decreases with MMF maintenance.
These associations were pronounced when the recipient has a donor more than 20 years
younger. It may be important to individualize immunosuppression regimens based on donor

and recipient characteristics. To help decrease the risk of fatal GVHD, avoidance of
basiliximab induction and the addition of MMF, when otherwise appropriate, may play a role
in high-risk LT patients.
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Figure and Table Legends
Figure 1. Adjusted hazards of fatal GVHD (graft-versus-host disease) according to
immunosuppression regimens.
Figure 2. Cumulative incidence of fatal GVHD (graft-versus-host disease) according to

A

C
C

EP

discrepancy > 20 years.

TE
D

immunosuppression regimens. A, all cohort; (B) age discrepancy  20 years; and (C) age
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Table 1. Comparison of background characteristics between fatal GVHD and all other patients.
All others
(n=77295)

Fatal GVHD
(n=121)

P

Age (years)

56.0 [49.0-62.0]

<0.001

BMI (kg/m2)

27.5 [24.2-31.7]

Recipient characteristics

Gender, n (%)

Male

51 802 (67.0)

60.0 [53.065.0]
26.9 [23.531.5]
83 (68.6)

Race, n (%)

White

55 430 (71.7)

87 (71.9)

0.134

Black

7410 (9.6)

18 (14.9)

-

Asian

3308 (4.3)

3 (2.5)

-

11 147 (14.4)

13 (10.7)

-

21.0 [14.0-30.0]

0.131

17 242 (22.3)

19.0 [11.028.8]
37 (30.6)

8841 (11.4)

9 (7.4)

0.198

22 530 (29.1)

34 (28.1)

0.837

18 955 (25.2)

24 (20.5)

0.287

20 848 (27.0)

27 (22.3)

0.240

Final MELD score
Diabetes, n (%)
Encephalopathy, n (%)
Ascites at LT, n (%)
Karnofsky score (10-30%), n (%)
HCV

EP

Primary diagnosisa, n (%)

5 (4.1)

NASH

6735 (8.7)

16 (13.2)

ALD

16 025 (20.7)

21 (17.4)

CLD

5913 (7.6)

6 (5.0)

AIH

1908 (2.5)

2 (1.7)

1591 (2.1)

5 (4.1)

22 161 (28.7)

39 (32.2)

16 291 (21.1)

30 (24.8)

0.317

4482 (5.8)

5 (4.1)

0.560

11 709 (15.1)

27 (22.3)

0.037

7478 (9.7)

10 (8.3)

0.758

40 430 (52.3)

61 (50.4)

0.716

1622 (2.1)

3 (2.5)

0.744

53 241 (68.9)

68 (56.2)

0.004

1344 (1.7)

5 (4.1)

0.061

2003-2007

21 060 (27.2)

35 (28.9)

0.391

2008-2012

25 433 (32.9)

45 (37.2)

2013-2018

30 802 (39.8)

41 (33.9)

C
C

2114 (2.7)

Others

HCC, n (%)

Retransplant, n (%)

A

Maintenance agent, n (%)

Basiliximab
rATG

Steroid
Rituximab
MMF
Azathioprine

Transplant year, n (%)

0.034

HBV

Metabolic

Induction agent, n (%)

0.768

TE
D

Others

0.253

Donor characteristics
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Age (years)

41.0 [26.0-54.0]

BMI (kg/m2)

26.3 [23.1-30.3]

Gender, n (%)
Donor type, n (%)
DCD donor, n (%)
Cold ischemia time (hours)
Recipient-Donor relationships

Male

45 955 (59.5)

31.0 [21.546.0]
25.4 [22.629.5]
87 (71.9)

Living

2837 (3.7)
3866 (5.0)
6.1 (4.8-8.0)

3 (2.5)
10 (8.3)
6.2 (5.0-7.4)

0.633
0.213
0.925

13.0 [0-28.0]
32 227 (41.7)

25.0 [7.540.0]
44 (36.4)
4 (5.9)

<0.001
0.268

Age discrepancy (years)
Gender mismatch, n (%)
HLA complete matchb, n (%)
n (%)

0.284
0.006

<0.001

TE
D

HLA class 1

matchb,

93 (0.3)

<0.001

185 (0.6)

7 (10.3)

<0.001

Bold type indicates statistically significant differences. aPatients with PBC or PSC were considered as CLD.
Alcoholic hepatitis was included in ALD. bThe complete match and class I match of HLA was recorded in
97 patients (0.1%) and 192 patients (0.2%), respectively. ALD, alcohol-related liver disease; AIH,
autoimmune hepatitis; BMI, body mass index; CLD, cholestatic liver disease; DCD, donation after
circulatory death; GVHD, graft-versus-host disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;

EP

HCV, hepatitis C virus; LT, liver transplantation; MELD, Model for End-stage Liver Disease; MMF,
mycophenolate mofetil; NASH, nonalcoholic steatohepatitis; PBC, xxx; PSC, xxx; rATG, rabbit anti-

A

C
C

thymocyte globulin.
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Table 2. Univariable and multivariable analysis of risk factors for fatal GVHD.
Variables

n

Univariable

Multivariable

HR (95% CI)

P

Male (Ref; female)

51 885

1.07 (0.73-1.58)

0.716

Age discrepancy > 20 years

28 929

2.64 (1.83-3.80)

<0.001

<20

397

Ref

21-40

6800

41-60

44 082

>60

26 137

<20

8086

Donor agea

41-60

29 841

>60

11 072

White

55 517

Black

7428

Asian

3311

Others

11 160

0.45 (0.06-3.29)

0.435

1.01 (0.14-7.29)

0.991

0.84 (0.51-1.40)

0.508

0.41 (0.23-0.72)

0.002

0.44 (0.22-0.91)
Ref

0.026

1.55 (0.93-2.58)

0.090

0.58 (0.12-1.82)

0.347

0.75 (0.42-1.34)

0.323

77 416

0.99 (0.97-1.01)

0.155

+

17 279

1.55 (1.05-2.28)

0.027

+

8850

0.63 (0.32-1.25)

0.188

+

22 564

0.96 (0.65-1.43)

0.841

+

18 979

0.79 (0.50-1.23)

0.294

Diabetes at LT
Encephalopathy at LT
Ascites at LT

Karnofsky score (10-30%)

+

18 926

0.85 (0.55-1.31)

0.455

AIH

+

2265

0.84 (0.27-2.65)

0.771

HCC

+

16 321

1.23 (0.81-1.85)

0.335

Retransplant

+

4487

1.18 (0.75-1.84)

0.477

Basiliximab induction

+

11 736

1.62 (1.05-2.48)

0.028

rATG induction

+

7488

0.84 (0.44-1.61)

0.773

Steroid induction

+

40 491

0.92 (0.65-1.32)

0.660

Rituximab induction

+

1625

1.17 (0.37-3.68)

0.790

MMF maintenance

+

53 309

0.56 (0.38-0.82)

0.003

74 576

1.50 (0.48-4.70)

0.491

2003-2007

21 095

Ref

2008-2012

25 478

1.06 (0.68-1.64)

0.805

2013-2018

30 843

0.83 (0.53-1.30)

0.407

+

97

21.82 (7.95-59.91)

<0.001

+

192

19.92 (9.11-43.54)

<0.001

A

ALD

Deceased (Ref; Living)
Transplant year

HLA complete matcha
HLA class 1

matcha

2.57 (1.78-3.71)

<0.001

Ref

C
C

Final MELD score

28 415

0.267

EP

Recipient race

21-40

0.30 (0.04-2.54)

P

TE
D

Recipient agea

HR (95% CI)

1.47 (1.00-2.17)

0.052

1.69 (1.10-2.61)

0.018

0.51 (0.35-0.75)

0.001
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Bold type indicates statistically significant differences. aRecipient and donor age were not included in the
multivariable analysis since these were components of the age discrepancy, and 2 factors regarding HLA
were not included because of the large number of missing values. AIH, autoimmune hepatitis; ALD, alcoholrelated liver disease; GVHD, graft-versus-host disease; HCC, hepatocellular carcinoma; HR, hazard ratio;
LT, liver transplantation; MELD, Model for End-stage Liver Disease; MMF, mycophenolate mofetil; rATG,

A

C
C

EP

TE
D

rabbit anti-thymocyte globulin.
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Table 3. Multivariable analysis of risk factors for fatal GVHD according to age discrepancy.
Variables

Age discrepancy ≤ 20 years
(n=48485)
HR (95% CI)

P

Age discrepancy > 20 years
(n=28929)
HR (95% CI)

P

Donor age

0.10 (0.98-1.02)

0.832

0.99 (0.97-1.02)

0.613

Diabetes at LT

0.80 (0.37-1.72)

0.567

1.99 (1.24-3.18)

0.004

Basiliximab induction

1.68 (0.83-3.40)

0.151

1.70 (0.98-2.95)

0.058

MMF maintenance

0.74 (0.38-1.44)

0.378

0.41 (0.25-0.67)

<0.001

Bold type indicates statistically significant differences. GVHD, graft-versus-host disease; HR, hazard ratio;

A

C
C

EP

TE
D

LT, liver transplantation; MMF, mycophenolate mofetil.
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